UroGen Pharma Ltd.
URGN
$9.87
-$0.24-2.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 24.57M | 25.20M | 21.85M | 18.78M | 23.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.57M | 25.20M | 21.85M | 18.78M | 23.53M |
| Cost of Revenue | 2.47M | 2.45M | 2.23M | 1.73M | 2.29M |
| Gross Profit | 22.09M | 22.75M | 19.62M | 17.05M | 21.24M |
| SG&A Expenses | 33.76M | 28.94M | 30.06M | 27.30M | 24.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.12M | 42.75M | 47.69M | 44.52M | 38.14M |
| Operating Income | -26.56M | -17.55M | -25.84M | -25.74M | -14.61M |
| Income Before Tax | -34.86M | -23.58M | -33.37M | -32.23M | -22.16M |
| Income Tax Expenses | 2.65M | 91.00K | 38.00K | 54.00K | 3.85M |
| Earnings from Continuing Operations | -37.51M | -23.67M | -33.40M | -32.29M | -26.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.51M | -23.67M | -33.40M | -32.29M | -26.02M |
| EBIT | -26.56M | -17.55M | -25.84M | -25.74M | -14.61M |
| EBITDA | -26.49M | -17.48M | -25.77M | -25.62M | -14.42M |
| EPS Basic | -0.80 | -0.55 | -0.91 | -0.97 | -0.72 |
| Normalized Basic EPS | -0.45 | -0.34 | -0.57 | -0.60 | -0.38 |
| EPS Diluted | -0.80 | -0.55 | -0.91 | -0.97 | -0.72 |
| Normalized Diluted EPS | -0.45 | -0.34 | -0.57 | -0.60 | -0.38 |
| Average Basic Shares Outstanding | 47.03M | 43.10M | 36.82M | 33.38M | 36.15M |
| Average Diluted Shares Outstanding | 47.03M | 43.10M | 36.82M | 33.38M | 36.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |